Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07037446

A Multicenter, International, Prospective and Retrospective, Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech Paravalvular Leak Device (PLD) in Patients With Mitral or Aortic Paravalvular Leaks

Sponsor: Occlutech International AB

View on ClinicalTrials.gov

Summary

This is an international, multicenter, retrospective and prospective post-marketing follow-up registry designed to monitor the safety and efficacy of the Occlutech Paravalvular Leak Device (PLD) in patients with clinically significant mitral or aortic paravalvular leaks after previously implanted prosthetic heart valves who undergo transcatheter PVL closure in routine clinical practice. Up to 200 subjects are planned to be enrolled and followed after the procedure (Day 1-7, Day 30, 6-12 months, and annually up to 3 years) to evaluate device safety (including serious adverse device effects) and effectiveness, including reduction of paravalvular regurgitation assessed by echocardiography and clinical outcomes such as improvement in heart failure symptoms and/or reduced need for hemolysis-related transfusions.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

200

Start Date

2025-02-05

Completion Date

2030-12-31

Last Updated

2026-07-31

Healthy Volunteers

No

Interventions

DEVICE

Transcatheter paravalvular leak closure device

Transcatheter closure of clinically significant mitral or aortic paravalvular leak (PVL) using the Occlutech Paravalvular Leak Device (PLD) in routine clinical practice. The PLD is an implantable occluder delivered percutaneously via catheter with the manufacturer-recommended delivery system and accessories, and deployed across the PVL under fluoroscopic and echocardiographic guidance (eg, TEE/3D TEE), according to the IFU and local standard of care. The procedure may be performed via an appropriate access route (eg, transseptal/retrograde/transapical) based on patient anatomy and operator assessment.

Locations (22)

Medical University of Silesia

Katowice, France

À l'Infirmerie Protestante de Lyon

Lyon, France

Hôpital Européen

Marseille, France

Hôpital Marie Lannelongue (Paris)

Paris, France

Deutsches Herzzentrum der Charité in Berlin

Berlin, Germany

University Hospital Dresden

Dresden, Germany

University Hospital Munich

München, Germany

Hippokration Hospital

Athens, Greece

Sotiria Hospital

Athens, Greece

Interbalkan European Medical Center, Heart Center Thessaloniki

Thessaloniki, Greece

Gottsegen National Cardiovascular Center

Budapest, Hungary

Medical School of the University

Szeged, Hungary

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain

İzmir Bayraklı Şehir Hastanesi

Izmir, Bayraklı, Turkey (Türkiye)

Gülhane Eğitim Araştırma Hastanesi

Ankara, Keçiören, Turkey (Türkiye)

Mehmet Akif Ersoy GKDC Eğitim Araştırma Hastanesi

Istanbul, Küçükçekmece, Turkey (Türkiye)

Tekirdağ Namık Kemal Üniversitesi Hastanesi

Tekirdağ, Süleymanpaşa, Turkey (Türkiye)

SBÜ Etlik Şehir Hastanesi Göğüs Kalp ve Damar Hastalıkları

Ankara, Yenimahalle, Turkey (Türkiye)

SBÜ Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi

Bursa, Yıldırım, Turkey (Türkiye)

Hacettepe Üniversitesi

Ankara, Turkey (Türkiye)

Kocaeli Üniversitesi Hastanesi

Kocaeli, Turkey (Türkiye)

Özel Ankara Güven Hastanesi

Ankara, Çankaya, Turkey (Türkiye)